

MAINTAINING HIGH TOUCH IN A HIGH-TECH HEALTH FUTURE:

Ethical and societal issues in multi-omics and digital health for end-of-life care in people with neurological conditions


JOHN NOEL VIANA^{1,2}

¹Australian National Centre for the Public Awareness of Science, ANU College of Science, The Australian National University, Canberra, Australia; ²Responsible Innovation Future Science Platform, Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia
E-mail: john.viana@anu.edu.au; LinkedIn: <https://www.linkedin.com/in/john-noel-via%C3%B1a-5114389/>




https://pcc4u.org.au/wp-content/uploads/2020/01/PCC4U_infographics_Module1_Figure2_WEB-1.png

Multi-omics for risk assessment and prognostication




(Redensek, Dolzan, and Kunej 2018)

Smart homes for motion monitoring



(Abbasi, Kenari, and Shamsi 2021)

Wearables for location and vital status monitoring



(Al-Naam et al. 2021)

TRANSLATION AND IMPLEMENTATION

- Clinical utility and impact on care provided, especially on advance care planning and access to EoL resources
- Prognostic accuracy and effect on disease outlook
- Evidence (sample size and study design) needed before implementation in hospital and community settings
- Intrusiveness, privacy, and security concerns
- Communication of findings to the person and caregivers

EQUITY, DIVERSITY, AND INCLUSION

- Motivations for and drivers of technology development
- Gender, racial/ethnic, and socio-economic diversity of sample sources and study participants
- Integration of these modalities in diverse settings, such as rural areas and under-resourced hospitals

IMPACT ON END-OF-LIFE CARE

- Role of the physician in interpreting findings
- Responsibilities of family and caregivers in monitoring health status and providing care
- High-tech technologies may impact the high-touch and warmth provided in end-of-life care
- Excessive quantification (measuring well vs living well)

This work is supported by the ANU-CSIRO Collaboration in Responsible Innovation in Precision Health. JNV acknowledges inputs from colleagues at the Australian National University (Joan Leach, Sujatha Raman, Brett Scholz, Imogen Mitchell, Caitlin Pilbeam, and Carys Fisser) and Monash University (Mark Howard and Zongyuan Ge). JNV does not have any conflicts of interest to disclose.